Key result
A Duchenne muscular dystrophy patient treated with antisense oligonucleotides 20 years ago was the only one among 8 patients of his generation to not develop heart failure.
Why the study?
Most patients with Duchenne muscular dystrophy die before age 30 from heart failure complications, prompting the long-term re-evaluation of a patient who received exon-skipping therapy 20 years earlier.
Does short-term exon-skipping therapy using antisense oligonucleotides preserve cardiac and respiratory function in patients with Duchenne muscular dystrophy?
Case Report (n=8)
Does short-term exon-skipping therapy using antisense oligonucleotides preserve cardiac and respiratory function in patients with Duchenne muscular dystrophy?
A short course of ASO exon-skipping therapy in a Duchenne muscular dystrophy patient was associated with preserved cardiac and respiratory function 20 years later, suggesting potential long-term cardioprotective benefits.
Answers are grounded in this paper and cite their sources.
Early ASO exon-skipping was associated with longer survival in one DMD case; leaves open cardiac benefit and requires prospective confirmation.
Duchenne muscular dystrophy (DMD) is a fatal, progressive muscle atrophy and most patients die before the age of 30 from complications of heart failure. We treated a DMD patient (Patient 0) with exon-skipping therapy using antisense oligonucleotides (ASO) for about one year 20 years ago. In this study, Patient 0 was re-evaluated based on hospital medical records using seven DMD patients of the same generation as controls Patient 0 was one of the youngest of the eight patients in terms of age at loss of ambulation, indicating that his disease progression was rapid prior to the start of the treatment. However, his age at the start of 24-h ventilator use was the second oldest of the eight patients, indicating slow disease progression after the end of the treatment. Patient 0, now 31 years old, had normal level of serum N-terminal pro-B-type natriuretic peptide, a marker of myocardial damage, and no heart failure level of left ventricular ejection fraction in cardiac function. Patient 0 was the only patient of his generation who did not have heart failure. These results suggest that short-term ASO treatment may be effective in preserving respiratory and cardiac function. However, these results were obtained in only one case, and need to be reconfirmed by accumulating long-term follow-up cases of ASO-treated patients in the future.
No takes yet. Share an insight, caveat, or question.
Ishikawa et al. (2025) conducted a case report in Duchenne muscular dystrophy (DMD) (n=8). Exon-skipping therapy using antisense oligonucleotides (ASO) vs. Seven DMD patients of the same generation was evaluated on Heart failure. A Duchenne muscular dystrophy patient treated with antisense oligonucleotides 20 years ago was the only one among 8 patients of his generation to not develop heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: